Lantern Pharma (LTRN) Other Non-Current Assets (2019 - 2026)
Lantern Pharma's (LTRN) quarterly Other Non-Current Assets came in at $26090.0 in Q1 2026, down 28.98% YoY from $36738.0 in Q1 2025, and down 28.98% on a QoQ basis from $36738.0 in Q4 2025.
Lantern Pharma (LTRN) Other Non-Current Assets (2019 - 2026) Analysis & Trends
Lantern Pharma (LTRN) has 8 years of Other Non-Current Assets data on file, last reported at $26090.0 in Q1 2026.
- Quarterly Other Non-Current Assets fell 28.98% year-over-year to $26090.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $26090.0 (down 28.98% YoY) and the FY2025 annual result came in at $36738.0, changed 0.0% from the prior year.
- Other Non-Current Assets eased to $26090.0 in Q1 2026, from $36738.0 in the prior quarter.
- In the past five years, Other Non-Current Assets ranged from a high of $541180.0 in Q1 2022 to a low of $25869.0 in Q2 2023.
- A 5-year average of $181641.7 and a median of $36738.0 in 2024 frame the typical range for Other Non-Current Assets.
- Annual changes were most pronounced in 2022 — Other Non-Current Assets surged 2925.21% — and 2023, when it plunged 95.22%.
- Tracing LTRN's Other Non-Current Assets over 5 years: stood at $541180.0 in 2022, then sank by 95.22% to $25869.0 in 2023, then jumped by 42.02% to $36738.0 in 2024, then changed by 0.0% to $36738.0 in 2025, then retreated by 28.98% to $26090.0 in 2026.
- The last three Other Non-Current Assets figures came in at $26090.0 (Q1 2026), $36738.0 (Q4 2025), and $36738.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 2.31 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 124.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 618.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 109.58 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 65.13 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 202.31 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 104.44 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 62.96 Mn |
| 10 | Lantern Pharma | 26.05 Mn | 26.05 Mn | - | 54,827.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 26,090.00 |
| Dec 31, 2025 | 36,738.00 |
| Sep 30, 2025 | 36,738.00 |
| Jun 30, 2025 | 36,738.00 |
| Mar 31, 2025 | 36,738.00 |
| Dec 31, 2024 | 36,738.00 |
| Sep 30, 2024 | 36,738.00 |
| Jun 30, 2024 | 32,015.00 |
| Mar 31, 2024 | 25,869.00 |
| Dec 31, 2023 | 25,869.00 |
| Sep 30, 2023 | 25,869.00 |
| Jun 30, 2023 | 25,869.00 |
| Mar 31, 2023 | 541,180.00 |
| Dec 31, 2022 | 541,180.00 |
| Sep 30, 2022 | 541,180.00 |
| Jun 30, 2022 | 541,180.00 |
| Mar 31, 2022 | 541,180.00 |
| Dec 31, 2021 | 17,889.00 |
| Sep 30, 2021 | 1.00 Mn |
| Jun 30, 2021 | 17,889.00 |